

# **Carlos Ramirez**

#### **Partner**



cramirez@cooley.com

+1 858 550 6157

San Diego

Public Companies Capital Markets Emerging Companies Venture Capital

Carlos practices corporate and securities law, with an emphasis on private and public company representation and capital markets transactions. He represents companies throughout their life cycles, including in private and public financings, mergers and acquisitions, corporate governance matters, and Securities and Exchange Commission (SEC) reporting and compliance. He also advises venture capital funds and investment banking firms in connection with financings.

Carlos routinely represents issuers and investors in complex securities offerings – including initial public offerings (IPOs), follow-on offerings, 144A offerings and private placements.

#### Carlos' select recent transactional experience includes advising:

- RayzeBio in its \$357.6 million IPO and \$4.1 billion acquisition by Bristol Myers Squibb
- Immunome in its \$200 million follow-on offering
- Structure Therapeutics in its \$300 million private investment in public equity (PIPE) and \$547.5 million follow-on offering
- CalciMedica in its PIPE of up to \$55 million
- Morphimmune in its merger with Immunome and \$125 million private placement
- ViaCyte in its sale to Vertex Pharmaceuticals for \$320 million
- Uber in its sale of a 50% stake in Careem's Super App to e&
- The Honest Company in its \$474.8 million IPO
- Uber in its offerings of \$1.5 billion 4.5% senior notes due 2029 and \$1.15 billion 0% convertible senior notes due 2025
- ASLAN Pharmaceuticals in several equity offerings with an aggregate value of \$125.7 million
- MannKind in its offering of \$230 million aggregate principal amount 2.5% convertible senior notes due 2026 and \$40 million follow-on offering
- Metacrine in its \$85 million IPO
- Vir Biotechnology in its \$142.9 million IPO and \$345 million follow-on offering
- Acadia Pharmaceuticals in several equity offerings with an aggregate value of \$525 million
- Allogene Therapeutics in its \$324 million IPO and \$632.5 million follow-on offering

Carlos serves as a member of Cooley's diversity committee and is actively engaged in the firm's diversity, equity and inclusion initiatives. In 2020, he was honored with a "Top Lawyers Under 40" Award from the Hispanic National Bar Association.

Carlos is a member of the board of directors of San Diego Squared (SD2), a San Diego STEM-focused nonprofit established in 2020 to connect underrepresented students to the power of science, technology, engineering and math by providing access to education, mentorship and the resources they need to lead the talent pipeline.

Before law school, Carlos was a senior associate in the audit practice for Deloitte, where he served private and public companies conducting audits and reviews of financial statements and internal controls. He is a former certified public accountant (CPA) in the state of California (license inactive).

### Education

Northwestern University Pritzker School of Law JD, 2013

Loyola Marymount University BBA, 2007

Loyola Marymount University BSA, 2007

### **Admissions & Credentials**

California

## Rankings & Accolades

Hispanic National Bar Association: Top Lawyers Under 40

## Memberships & Affiliations

American Bar Association (ABA)

San Diego County Bar Association

Hispanic National Bar Association (HNBA)